0001179110-17-012310.txt : 20170914
0001179110-17-012310.hdr.sgml : 20170914
20170914202116
ACCESSION NUMBER: 0001179110-17-012310
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170912
FILED AS OF DATE: 20170914
DATE AS OF CHANGE: 20170914
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HBM Healthcare Investments (Cayman) Ltd.
CENTRAL INDEX KEY: 0001232258
STATE OF INCORPORATION: E9
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37558
FILM NUMBER: 171086659
BUSINESS ADDRESS:
STREET 1: 2454 WEST BAY ROAD, 3RD FLOOR
CITY: GRAND CAYMAN
STATE: E9
ZIP: 00000
BUSINESS PHONE: 1 345 946 8002
MAIL ADDRESS:
STREET 1: P.O BOX 30852
CITY: GRAND CAYMAN
STATE: E9
ZIP: KY1-1204
FORMER NAME:
FORMER CONFORMED NAME: HBM BIOVENTURES CAYMAN LTD
DATE OF NAME CHANGE: 20030512
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nabriva Therapeutics plc
CENTRAL INDEX KEY: 0001641640
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 56 FITZWILLIAM SQUARE
CITY: DUBLIN
STATE: L2
ZIP: 2
BUSINESS PHONE: (610) 816-6640
MAIL ADDRESS:
STREET 1: 1000 CONTINENTAL DRIVE
STREET 2: SUITE 600
CITY: KING OF PRUSSIA
STATE: PA
ZIP: 19406
FORMER COMPANY:
FORMER CONFORMED NAME: Nabriva Therapeutics AG
DATE OF NAME CHANGE: 20150507
4
1
edgar.xml
FORM 4 -
X0306
4
2017-09-12
1
0001641640
Nabriva Therapeutics plc
NBRV
0001232258
HBM Healthcare Investments (Cayman) Ltd.
GOVERNORS SQUARE, SUITE #4-212-2
23 LIME TREE BAY AVE., WEST BAY
GRAND CAYMAN
E9
00000
CAYMAN ISLANDS
0
0
1
0
Ordinary Shares
2017-09-12
4
S
0
10458
8.6284
D
2360278
D
Ordinary Shares
2017-09-13
4
S
0
22721
8.5364
D
2337557
D
Ordinary Shares
2017-09-14
4
S
0
3429
8.5225
D
2334128
D
The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $8.53 to $8.825. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price.
The balance was adjusted by one (1) share to account for a mathematical error in a prior filing.
The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $8.5 to $8.685. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price
The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $8.5 to $8.6386. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price.
/s/ Jean-Marc Lesieur, Director
2017-09-14